• Everolimus (Afinitor) has been approved by the European Commission for treatment of unresectable or metastatic, well-differentiated (grade 1 or grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or […] Read more
By Erik J. MacLaren, PhD Liquid Biopsy Testing On June 1, 2016, the U.S. Food and Drug Administration (FDA) approved the use of the cobas EGFR Mutation Test v2 to […] Read more
By Prof. Corinne Faivre-Finn The optimal timing and schedule of thoracic radiation in the management of limited-stage small cell lung cancer (LS-SCLC) continues to provoke debate. Since the publication of […] Read more
By James L. Mulshine, MD On June 13, 2016, the Prevent Cancer Foundation hosted the 13th Annual Quantitative Imaging Workshop: Lung Cancer, COPD and Cardiovascular Disease – Exploring the Intersections. […] Read more
On July 31, 2016, the lung cancer and oncology research community lost a respected researcher and leader, Gregory Curt, MD, who died at the US Walter Reed National Military Medical […] Read more
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published online in April 2013 the original “Molecular Testing […] Read more
By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can benefit from EGFR tyrosine kinase […] Read more
By Erik J. MacLaren, PhD Blue Ribbon Panel of the US National Cancer Advisory BoardDuring his State of the Union address in January 2016, President Barack Obama announced a new […] Read more
By Adi F. Gazdar, MD While all of the major histological forms of lung cancer are strongly associated with smoking, an important subset (about 20% worldwide, 10–15% in the US) […] Read more
By Cynthia L. Kryder, MS Roswell Park Cancer Institute in Buffalo, New York, US, expects to be the site for the first US clinical trial of CimaVax, the groundbreaking lung […] Read more